Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen (NASDAQ:AMGN) has announced its participation in the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 10:00 a.m. ET. Three executive leaders will participate in a fireside chat: Peter Griffith (EVP and CFO), Jay Bradner (EVP of Research and Development, CSO), and Susan Sweeney (EVP of Obesity and Related Conditions).
The presentation will be accessible through a live webcast on Amgen's website (www.amgen.com) under the Investors section. The webcast will remain available for replay for at least 90 days following the event.
Amgen (NASDAQ:AMGN) reported positive 52-week Phase 2 study results for MariTide, a monthly or less frequent subcutaneous treatment for obesity. The drug achieved ~20% average weight loss in people with obesity/overweight without Type 2 diabetes, and ~17% weight loss in those with Type 2 diabetes, alongside a 2.2 percentage point reduction in HbA1c. No weight loss plateau was observed, suggesting potential for further weight reduction. The treatment showed improvements in cardiometabolic parameters and had manageable gastrointestinal side effects. The discontinuation rate in dose escalation arms was ~11%. Amgen announced the initiation of MARITIME, a Phase 3 program for obesity and related conditions.
Amgen (NASDAQ:AMGN) announced a webcast scheduled for November 26, 2024, at 5 a.m. PT to discuss the results of their 52-week Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and its development program progress. The presentation will feature CEO Robert A. Bradway and other senior management team members. The webcast will be accessible to investors, media, and the public through Amgen's website, with replay available for at least 90 days after the event.
Amgen (NASDAQ:AMGN) has appointed Howard Chang, M.D., Ph.D. as senior vice president of Research and chief scientific officer, effective December 16, 2024. Reporting to Jay Bradner, executive vice president of R&D, Chang will lead research priorities across rare disease, oncology, inflammation, and cardiometabolic therapeutic areas. He will oversee operations in research hubs from San Francisco to Thousand Oaks, and across global sites in Reykjavik, Copenhagen, Munich, British Columbia, and Maryland. Chang succeeds Ray Deshaies, Ph.D., whose departure was announced earlier this year.
Amgen presented new data for its rare disease treatments at ACR 2024, highlighting significant results for UPLIZNA and KRYSTEXXA. The MITIGATE Phase 3 study showed UPLIZNA reduced IgG4-RD flare risk by 87% compared to placebo, with 57.4% of patients achieving flare-free complete remission at Week 52. The AGILE trial demonstrated that KRYSTEXXA with methotrexate administered in 60-minute infusions maintained efficacy, with 67.2% of participants achieving target urate levels. The FDA granted Breakthrough Therapy Designation for UPLIZNA in IgG4-RD, and regulatory filings are underway for both treatments.
Amgen (NASDAQ:AMGN) has released a statement regarding the Phase 1 data of MariTide (maridebart cafraglutide, formerly AMG 133). The company affirms there is no apparent connection between MariTide administration and bone mineral density changes. Amgen maintains that the Phase 1 study results do not indicate any bone safety concerns and do not affect their confidence in MariTide's potential. The company plans to release Phase 2 topline data later this year.
Amgen (NASDAQ:AMGN) has announced its participation in the 2024 UBS Global Healthcare Conference. Peter Griffith, executive vice president and CFO, will represent the company on Wednesday, Nov. 13, 2024, at 10:15 a.m. PT.
The presentation will be accessible through a live webcast available to investors, media, and the public. The webcast can be accessed on Amgen's website under the Investors section and will remain available for replay for at least 90 days following the event.
Amgen and AstraZeneca announced positive top-line results from the Phase 3 WAYPOINT trial of TEZSPIRE in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial showed statistically significant and clinically meaningful reductions in both nasal polyp size and nasal congestion compared to placebo. The study evaluated TEZSPIRE's efficacy in adults with severe CRSwNP who remained symptomatic despite standard intranasal corticosteroid treatment. The safety profile was consistent with previous findings.
Amgen (NASDAQ:AMGN) reported strong Q3 2024 financial results with total revenues increasing 23% to $8.5 billion. Product sales grew 24%, driven by 29% volume growth, partially offset by 2% lower net selling price. Ten products delivered double-digit sales growth, including Repatha, TEZSPIRE, and BLINCYTO. The company reported $1.2 billion in rare disease product sales. GAAP EPS increased 62% to $5.22, while Non-GAAP EPS rose 13% to $5.58. Free cash flow generation was $3.3 billion, up from $2.5 billion in Q3 2023. The company updated its full-year 2024 guidance, expecting total revenues between $33.0-33.8 billion.
Amgen (NASDAQ:AMGN) has announced its fourth quarter 2024 dividend payment. The company's Board of Directors has declared a dividend of $2.25 per share. Shareholders who are recorded as stockholders at the close of business on November 18, 2024, will receive the dividend payment on December 9, 2024.
